Deciphera gets FDA orphan drug designation for DCC-2618 to treat glioblastoma multiforme and anaplastic astrocytoma
Glioblastoma multiforme and anaplastic astrocytoma are the most common and most severe forms of non-metastatic brain cancer. According to the Central Brain Tumor Registry of the United States,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.